Trevi Therapeutics, Inc.

Historical 13F Holders

Symbol
TRVI
CUSIP
89532M101
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 89532M101 since 12/18/2024, largest first.

Filer % of Class Filed
New Enterprise Associates 16, L.P. 13D/A
10.5% 5/7/2026
Event 5/5/2026
FMR LLC 13G/A
8.8% 8/6/2026
Event 6/30/2026
BlackRock, Inc. 13G/A 6.9% 10/27/2026
Event 9/30/2026
Frazier Life Sciences Public Fund, L.P. 13G/A
5.5% 11/16/2026
Event 9/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (5)
Viking Global Investors LP 13G/A
4.2% 11/14/2025
Event 9/30/2025
Rubric Capital Management LP 13G/A
2.9% 2/13/2026
Event 12/31/2025
Venrock Healthcare Capital Partners II, L.P. 13G/A
1.4% 2/14/2025
Event 12/31/2024
Rosalind Advisors, Inc. 13G/A
1.2% 2/13/2025
Event 2/13/2025
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 226 151 M $2.17B
2026 Q2 221 149 M $2.76B
2026 Q1 201 135 M $1.61B
2025 Q4 185 130 M $1.63B
2025 Q3 168 131 M $1.19B
2025 Q2 157 115 M $627M
2025 Q1 141 88.1 M $554M
2024 Q4 111 79.5 M $330M
2024 Q3 94 58.1 M $194M
2024 Q2 79 55.9 M $167M
2024 Q1 81 51.6 M $178M
2023 Q4 64 52.2 M $70.0M
2023 Q3 56 48.7 M $106M
2023 Q2 54 48.8 M $117M
2023 Q1 37 43.5 M $80.4M
2022 Q4 38 43.2 M $83.3M
2022 Q3 41 45.8 M $70.5M
2022 Q2 33 28.8 M $80.8M
2022 Q1 24 7.16 M $32.9M
2021 Q4 18 13.2 M $10.3M
2021 Q3 19 12.4 M $17.4M
2021 Q2 18 12.5 M $28.1M
2021 Q1 20 13.1 M $35.6M
2020 Q4 19 13.0 M $31.7M
2020 Q3 17 13.3 M $53.5M
2020 Q2 17 13.4 M $88.0M
2020 Q1 21 14.0 M $45.9M
2019 Q4 17 14.2 M $53.2M
2019 Q3 21 14.1 M $63.5M
2019 Q2 19 14.2 M $106M